Custom synthesis and Lifescience tools made by SiChem
Sirius Fine Chemicals SiChem GmbH synthesizes APIs for early stage (Toxicology) drug design. A special field of expertise is the preparation of biologically and pharmacologically active compounds with increased bioavailability (prodrugs).
We are one of the leading providers for inositol phosphates as well as a large variety of membranepermeant and photoactivatable derivatives. Our portfolio has recently been supplemented by clickable unnatural amino acids and other useful tools for Click-Chemistry.
New : PHYCOCYANOBILIN (PCB) SC-1800
PCB is the essential chromophore of the PhyB-PIF optogenetic system. This allows to control protein localisation subcellularly
”SiChem’s PCB is working marvelously” says Dr. Alba Diz-Muñoz, Group Leader, EMBL
Buckley et al., 2016, Developmental Cell 36,
117–126 January 11, 2016
SiChem - member of the i3 - Life Sciences Cluster - is a " Landmark in the Land of Ideas"
The competition " 100 Landmarks in the Land of Ideas" promotes ideas for urgent issues of tomorrow. The i3 - Life Sciences Cluster tries to find answers to the increasing life expectancy and the associated diseases. Innovative diagnostic companies in the Bremen / Bremerhaven region have joined forces to investigate biomarkers that may indicate certain diseases more accurately.
INO-4995 has potential in treatment of Cystic Fibrosis (CF)
INO-4995 (1-O-octyl-2-O-butyryl-D-myo-inositol 3,4,5,6-tetrakisphosphate octakis(propionoxymethyl)ester) is an ion channel modulator that is slowly metabolized in cells. Studies have shown that it inhibits ENaC activity while promoting expression of the calcium-activated chloride channel, TMEM16a, in membranes. Thus it has potential therapeutic activity in the treatment of cystic fibrosis where it normalized nasal potential difference (npd) in a murine CF knock-out model and promoted fluid secretion in human CF airway epithelia.
Strong preclinical efficacy of INO-4995: a membrane-permeant Inositol-phosphate derivative has potential in treatment of Cystic Fibrosis (CF)
This graph is showing the difference in npd between mice before and after 4-day treatment with INO-4995 (0.0008mg/kg):
Am J Respir Cell Mol Biol 2010, 42(1), 105
PDP3: New Tool to study the biology of Protein Phosphatase-1 (PP1)
SiChem expanded its portfolio toward peptides: PP1-Disrupting Peptides (PDPs) can be used as selective tools to study acute and long-term effects of PP1 activation in intact cells. This membrane-permeant peptide competes with endogenous, the motif RVxF containing PIPs to bind to PP1 in living cells. This PDP3 does not bind to the closely related phosphatase PP2A.
In addition, PDPs can be used to sensitize cells for clinically relevant kinase inhibitors (SC-0100)
Rapidly reversible Chemical Dimerizer rCD1 is now available at SiChem
The first rapidly reversible chemical dimerization system – rCD1 - , which permits to determine kinetics of lipid metabolizing enzymes in living cells, is now available at SiChem . This new system was applied to induce and stop the activity of phosphatidyl 3-kinase (PI3K) (product information) rCD1 is available in 2 sizes: 100µg (for app. 20 experiments) and 500µg (SC-7000)
Chemical Dimerizer rCD1
A representative time-lapse fluorescence movie of HeLa cells co-transfected
with NLS2-SNAPf-ECFP and mRFP-FKBP constructs. rCD1 (1 μM) induces
translocation of mRFP-FKBP into the nucleus; addition of FK506 (1 μM) leads to
release of mRFP-FKBP from the nucleus !
New Click-Amino Acids for In Vivo Protein Labeling - now available at SiChem !
There is a growing demand in advanced fluorescence microscopy for small and highly photostable fluorescent probes. These probes consists of unnatural clickable Amino Acids (UAAs) which can be labeled in vivo with a clickable dye. The corresponding click-Amino Acids are now available at SiChem.
Insulin Receptors - expressed with two unnatural amino acids (UAAs) TCO*A (SC-8008) and SCO (SC-8000) labeled with Cy5-CH3-Tetrazin (cyan) und Atto532-H-Tetrazin (magenta)
(Nikic et al. Angew. Chem. Int. Ed. 2014, 53 (8): 2245)